Pfizer, PhRMA back SOPA amid online protests

With dozens of websites blocked in protest of new anti-piracy legislation, Pfizer ($PFE) and PhRMA are among the intellectual-property champions that are lobbying for, rather than against, the proposed laws. Pfizer says the measures--one approved by the House, another by the Senate--would help prevent drug counterfeiting. Report

Suggested Articles

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.